Castuner

BioSpace

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Сайт подкаста

Слушайте в своём приложении

Эпизоды

283 эпизода

  1. Can we finally get ahead of drug shortages? 20:47
  2. Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November 23:50
  3. Beyond the needle: The future of intratumoral therapy 21:02
  4. Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review 23:00
  5. Stability, speed and strategy: Inside Australia’s early‑stage edge 21:19
  6. Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025 23:34
  7. Why investors are taking another look at kidney disease 18:26
  8. Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners 17:49
  9. Bonus: Q3 2026 Job Market Update 16:20
  10. The decisions behind scientific progress 10:52
  11. J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback 19:48
  12. Beyond equity: Why venture debt is reshaping European biotech 22:35
  13. Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more 24:18
  14. The race for access: How the FAIR Act could reclaim U.S. biotech leadership 20:28
  15. AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll 20:09
  16. How radioligand therapy is rewriting cancer care 15:38
  17. Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz 21:21
  18. When vision fades: Rethinking wet AMD and the durability gap 21:35
  19. FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival 22:11
  20. The supply chain fault lines of modern pharma 36:20
  21. Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease 20:19
  22. Breaking borders: Building biotech scale in Benelux 18:34
  23. Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals 20:23
  24. Fragile X at a turning point: Breaking through the clinical bottleneck 19:23
  25. Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed 23:27
  26. Rewriting the rules of CMV prevention 19:39
  27. Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more 19:08
  28. The Italian inflection point: Clinical strength, culture and capital 18:54
  29. Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight 19:01
  30. Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms 23:14
  31. The next treatment-resistant depression paradigm 20:18
  32. Life after the lead asset: Advancing an early-stage pipeline 24:01
  33. Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more 17:10
  34. Nordic biotech’s next act: From fragmentation to global force 20:18
  35. Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2 21:20
  36. The future of pain relief: Exploring opioid alternatives 19:11
  37. Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup 21:22
  38. Bonus: Q2 2026 Job Market Update 9:01
  39. From sequence to scale: Gene editing’s new era in biologics manufacturing 20:41
  40. Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil 17:04
  41. Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water 22:54
  42. The Golden Triangle and the gaps: Rethinking UK biotech 19:37
  43. AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more 21:36
  44. From fragile skin to living medicine: Lessons from RDEB 21:43
  45. Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more 25:33
  46. Portugal, Spain and the new biotech frontier 20:33
  47. Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence 25:02
  48. Rethinking hair loss treatment 21:45
  49. ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck 27:04
  50. France’s biotech ecosystem: science, capital and scale 21:00